Our hypothesis is that MS grey matter pathology, and thereby disease burden and clinical outcome, can be better predicted by looking at damage in the connected white matter in early RRMS patients
ID
Bron
Verkorte titel
Aandoening
multiple sclerosis; white matter damage; grey matter atrophy
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Three measures for WM damage will be assessed, i.e. lesion volume, lesion fractional anisotropy (FA) and NAWM FA, from which a composite WM damage score will be computed. High versus low WM damage scores will then be compared to the atrophy rates in the GM, based on subcortical volume and cortical thickness measures. From this, we can compare atrophy rates of each GM structure from baseline to year 1 between the group of patients with higher damage in the WM tracts connected to that GM structure on the one hand, and the group of patients with lower damage in those WM tracts on the other.<br>
Similar calculations will be performed between year 1 and year 2 in order to determine whether a larger increase of WM damage over the first study year is predictive of faster subsequent GM atrophy in the second year.
Doel van het onderzoek
Our hypothesis is that MS grey matter pathology, and thereby disease burden and clinical outcome, can be better predicted by looking at damage in the connected white matter in early RRMS patients
Onderzoeksopzet
Baseline (year 0), year 1 and year 2
Onderzoeksproduct en/of interventie
None
Publiek
Merlin M. Weeda
De Boelelaan 1118
Amsterdam 1081 HZ
The Netherlands
T: +31 (0) 20 444 0225
E: M.Weeda@vumc.nl
Wetenschappelijk
Merlin M. Weeda
De Boelelaan 1118
Amsterdam 1081 HZ
The Netherlands
T: +31 (0) 20 444 0225
E: M.Weeda@vumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Patient group:
1. Minimum age 18 years
2. Clinically definite relapsing remitting MS for < 5 years
3. Either receiving no treatment, or receiving first line treatment for at least 6 months
4. Expanded Disability Status Score (EDSS) ≤ 5.0
5. Written informed consent
Control group:
1. Minimum age 18 years
2. Written informed consent
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Past or current clinically relevant non-MS neurological or psychiatric disorder(s)
2. Past or current clinically relevant (auto)immune disorder(s)
3. Treatment for MS with first line therapy for less than 6 months
4. Treatment for MS with second line therapy
5. Relapse and/or steroid treatment in past 3 months
6. Pregnancy
7. MRI incompatibility, e.g. metal objects in or around the body, claustrophobia or inability to lie still in the scanner
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL5923 |
NTR-old | NTR6103 |
Ander register | METc VUmc : 2016.314 |